Ken Griffin Altimmune, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Altimmune, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 266,300 shares of ALT stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

266,300

Previous 315,700 15.65%

Holding current value

$1.99 Million

Previous $3.21 Million 44.91%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $443,521 - $767,720	-75,046 Reduced 98.66%	1,021 $6,000
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $625,270 - $1.05 Million	76,067 New	76,067 $774,000
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $507,420 - $729,416	-211,425 Reduced 63.91%	119,404 $310,000
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $5.91 Million - $10.2 Million	-1,713,656 Reduced 83.82%	330,829 $1.17 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $3.71 Million - $14.9 Million	885,024 Added 76.33%	2,044,485 $8.63 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $9 Million - $16.9 Million	1,030,210 Added 797.06%	1,159,461 $19.1 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $10.9 Million - $22.8 Million	-1,018,607 Reduced 88.74%	129,251 $1.65 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $92,396 - $276,018	23,451 Added 2.09%	1,147,858 $13.4 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $510,072 - $816,980	86,453 Added 8.33%	1,124,407 $6.85 Million
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $450,993 - $647,687	-51,898 Reduced 4.76%	1,037,954 $9.51 Million
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $1.69 Million - $3.38 Million	-201,013 Reduced 15.57%	1,089,852 $12.3 Million
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $1.58 Million - $2.64 Million	160,606 Added 14.21%	1,290,865 $12.7 Million
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $259,474 - $496,288	20,415 Added 1.84%	1,130,259 $16 Million
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $5.21 Million - $9.45 Million	664,907 Added 149.44%	1,109,844 $12.5 Million
Q3 2020 Nov 16, 2020	SELL	$9.93 - $33.26 $1.23 Million - $4.12 Million	-123,960 Reduced 21.79%	444,937 $5.87 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $1.58 Million - $5.83 Million	544,578 Added 2239.31%	568,897 $6.09 Million
Q4 2019 Feb 14, 2020	BUY	$1.53 - $2.15 $11,161 - $15,684	7,295 Added 42.85%	24,319 $46,000
Q3 2019 Nov 14, 2019	SELL	$1.95 - $2.66 $15,190 - $20,721	-7,790 Reduced 31.39%	17,024 $33,000
Q2 2019 Aug 14, 2019	BUY	$2.19 - $3.4 $25,695 - $39,892	11,733 Added 89.69%	24,814 $59,000
Q1 2019 May 15, 2019	BUY	$2.54 - $4.54 $33,225 - $59,387	13,081 New	13,081 $0

Others Institutions Holding ALT

# of Institutions

190

Shares Held

42.2M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $366M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account